2023
Preliminary results of a phase II trial with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2.
Santin A, McNamara B, Siegel E, Harold J, Mutlu L, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Dottino P, Schwartz P, Bellone S. Preliminary results of a phase II trial with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2. Journal Of Clinical Oncology 2023, 41: 5599-5599. DOI: 10.1200/jco.2023.41.16_suppl.5599.Peer-Reviewed Original ResearchRecurrent endometrial carcinomaSacituzumab govitecan-hziyTrop-2 overexpressionPhase 2 trialEndometrial carcinomaUterine serous carcinomaTrop-2Endometrioid adenocarcinomaSerous carcinomaClinical activityMetastatic triple-negative breast cancerAnti-Trop-2 antibodyGrade 3 endometrioid adenocarcinomaTriple-negative breast cancerAdequate bone marrowUnexpected safety signalsMetastatic urothelial cancerClear cell histologyPhase II trialSystemic corticosteroid usePlatinum-based chemotherapyFavorable safety profileDurable disease controlRemarkable clinical activityStage 1
2020
Novel antibody-drug conjugates: current and future roles in gynecologic oncology.
Tymon-Rosario J, Zeybek B, Santin AD. Novel antibody-drug conjugates: current and future roles in gynecologic oncology. Current Opinion In Obstetrics & Gynecology 2020, 33: 26-33. PMID: 32618744, PMCID: PMC8253558, DOI: 10.1097/gco.0000000000000642.Peer-Reviewed Original ResearchConceptsAntibody-drug conjugatesAntigen-negative cellsNovel antibody-drug conjugateAggressive gynecologic malignancyReceptor-targeting antibodiesTrop-2 overexpressionOngoing clinical trialsHER2/neuPersonalized cancer careNormal surrounding tissueAntigen-positive target cellsGynecologic malignanciesGynecologic tumorsCervical cancerSacituzumab govitecanCancer careGynecologic oncologyPreclinical dataTrastuzumab emtansineADC therapyClinical trialsMultiple tumorsCurrent standard practiceNoncleavable linkerCytotoxic molecules
2012
Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma
Bignotti E, Zanotti L, Calza S, Falchetti M, Lonardi S, Ravaggi A, Romani C, Todeschini P, Bandiera E, Tassi RA, Facchetti F, Sartori E, Pecorelli S, Roque DM, Santin AD. Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma. BMC Clinical Pathology 2012, 12: 22. PMID: 23151048, PMCID: PMC3534488, DOI: 10.1186/1472-6890-12-22.Peer-Reviewed Original ResearchDisease-free survivalEndometrioid endometrial carcinomaTrop-2 overexpressionProgression-free survivalIndependent prognostic factorHigh tumor gradePrognostic factorsEndometrial carcinomaTumor gradeMultivariate analysisTrop-2 protein expressionPoor disease-free survivalReduced disease-free survivalProtein expressionAdvanced FIGO stageCommon gynecologic malignancyEndometrioid endometrial cancerLymphovascular space invasionProtein overexpressionParaffin-embedded specimensAggressive tumor phenotypeSurgical stagingCervical involvementMedical comorbiditiesEndometrial cancer
2011
Trop-2 Overexpression in Poorly Differentiated Endometrial Endometrioid Carcinoma
Bignotti E, Ravaggi A, Romani C, Falchetti M, Lonardi S, Facchetti F, Pecorelli S, Varughese J, Cocco E, Bellone S, Schwartz PE, Rutherford TJ, Santin AD. Trop-2 Overexpression in Poorly Differentiated Endometrial Endometrioid Carcinoma. International Journal Of Gynecological Cancer 2011, 21: 1613-1621. PMID: 21892093, PMCID: PMC3233648, DOI: 10.1097/igc.0b013e318228f6da.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibody-Dependent Cell CytotoxicityAntigens, NeoplasmCarcinoma, EndometrioidCell Adhesion MoleculesCell DifferentiationCell Line, TumorComplement System ProteinsEndometrial NeoplasmsFemaleFlow CytometryHumansImmunization, PassiveImmunoglobulin GImmunohistochemistryRNA, MessengerConceptsEndometrial endometrioid carcinomaNormal endometrial controlsTrop-2 expressionEEC cell linesAntibody-dependent cellular cytotoxicityReal-time polymerase chain reactionQuantitative real-time polymerase chain reactionEndometrioid carcinomaPolymerase chain reactionCellular cytotoxicityTrop-2Anti-Trop-2 antibodyCell linesTherapeutic agentsCr-release assaysTrop-2 overexpressionGrade 3 tumorsStandard treatment modalityChain reactionNovel therapeutic agentsCell surface markersEndometrial controlTreatment modalitiesPrimary cell linesEEC samples
2010
Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients
Bignotti E, Todeschini P, Calza S, Falchetti M, Ravanini M, Tassi RA, Ravaggi A, Bandiera E, Romani C, Zanotti L, Tognon G, Odicino FE, Facchetti F, Pecorelli S, Santin AD. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. European Journal Of Cancer 2010, 46: 944-953. PMID: 20060709, DOI: 10.1016/j.ejca.2009.12.019.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerTrop-2 overexpressionTrop-2 expressionOverall survivalPrognostic factorsProtein overexpressionTrop-2 protein expressionMultivariate Cox regression analysisConventional clinicopathological featuresPresence of ascitesCox regression analysisLymph node metastasisOvarian carcinoma patientsPoor overall survivalIndependent prognostic markerNovel prognostic factorUnivariate survival analysisAggressive malignant phenotypeImmunotherapeutic strategiesShort-term cultureCarcinoma patientsClinical courseNode metastasisClinicopathological featuresPrognostic significance